Salvinorin A Inhibits Airway Hyperreactivity Induced by Ovalbumin Sensitization by Antonietta Rossi et al.
fphar-07-00525 January 12, 2017 Time: 15:50 # 1
ORIGINAL RESEARCH
published: 13 January 2017
doi: 10.3389/fphar.2016.00525
Edited by:
Giovanni Li Volti,
University of Catania, Italy
Reviewed by:
Marco Aurélio Martins,
Oswaldo Cruz Foundation, Brazil
Inmaculada Posadas,
University of Castilla-La Mancha,
Spain
*Correspondence:
Antonietta Rossi
antrossi@unina.it
Raffaele Capasso
rafcapas@unina.it
Specialty section:
This article was submitted to
Experimental Pharmacology and Drug
Discovery,
a section of the journal
Frontiers in Pharmacology
Received: 29 September 2016
Accepted: 19 December 2016
Published: 13 January 2017
Citation:
Rossi A, Caiazzo E, Bilancia R,
Riemma MA, Pagano E, Cicala C,
Ialenti A, Zjawiony JK, Izzo AA,
Capasso R and Roviezzo F (2017)
Salvinorin A Inhibits Airway
Hyperreactivity Induced by Ovalbumin
Sensitization.
Front. Pharmacol. 7:525.
doi: 10.3389/fphar.2016.00525
Salvinorin A Inhibits Airway
Hyperreactivity Induced by
Ovalbumin Sensitization
Antonietta Rossi1*, Elisabetta Caiazzo1, Rossella Bilancia1, Maria A. Riemma1,
Ester Pagano1, Carla Cicala1, Armando Ialenti1, Jordan K. Zjawiony2, Angelo A. Izzo1,
Raffaele Capasso1,3* and Fiorentina Roviezzo1
1 Department of Pharmacy, University of Naples Federico II, Naples, Italy, 2 Department of BioMolecular Sciences, Division of
Pharmacognosy and the Research Institute of Pharmaceutical Sciences, School of Pharmacy, University of Mississippi,
University, MS, USA, 3 Department of Agricultural Sciences, University of Naples Federico II, Portici, Italy
Salvinorin A, a neoclerodane diterpene isolated from Salvia divinorum, exerts a number
of pharmacological actions which are not solely limited to the central nervous system.
Recently it has been demonstrated that Salvinorin A inhibits acute inflammatory
response affecting leukotriene (LT) production. Since LTs are potent lipid mediators
implicated in allergic diseases, we evaluated the effect of Salvinorin A on allergic
inflammation and on airways following sensitization in the mouse. Mice were sensitized
with s.c. injection of ovalbumin (OVA) on days 1 and 8. Sensitized mice received
on days 9 and 12 on the shaved dorsal surface air administration to induce the
development of the air-pouches. On day 15 animals were challenged by injection of
OVA into the air-pouch. Salvinorin A, administered (10 mg/kg) before each allergen
exposure, significantly reduced OVA-induced LT increase in the air pouch. This effect
was coupled to a reduction in cell recruitment and Th2 cytokine production. In another
set of experiments, mice were sensitized with OVA and both bronchial reactivity and
pulmonary inflammation were assessed. Salvinorin A abrogated bronchial hyperreactivity
and interleukin (IL)-13 production, without effect on pulmonary inflammation. Indeed cell
infiltration and peribronchial edema were still present following diterpenoid treatment.
Similarly, pulmonary IL-4 and plasmatic IgE levels were not modulated. Conversely,
Salvinorin A significantly reduced LTC4 production in the lung of sensitized mice. Finally
mast cell activity was evaluated by means of toluidine blue staining. Data obtained
evidenced that Salvinorin A significantly inhibited mast cell degranulation in the lung.
Our study demonstrates that Salvinorin A inhibits airway hyperreactivity induced by
sensitization by inhibition of LT production and mast cell degranulation. In conclusion
Salvinorin A could represent a promising candidate for drug development in allergic
diseases such as asthma.
Keywords: Salvinorin A, leukotrienes, asthma, airway hyperreactivity, mast cells
Abbreviations: Cys-LTs, cysteinyl-leukotrienes; H&E, haematoxylin and eosin; IL, interleukin; LTs, leukotrienes; MPO,
myeloperoxidase; OVA, ovalbumin.
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INTRODUCTION
The plant Salvia divinorum, that occurs naturally in Mexico,
has been used for centuries to facilitate spiritual experiences in
religious rituals as well as employed by shamans for the cure
of various disorders, including those characterized by having an
inflammatory/allergic component (Vortherms and Roth, 2006;
Mahendran et al., 2016). S. divinorum is actually primarily
used by adolescent and young adults for its hallucinogenic
properties with a prevalence of use ranging, for example, from
1.3% among adults in the USA to 11% of attendees to rave
musical events in Italy (Mahendran et al., 2016). The main active
ingredient of the plant is the neoclerodane diterpenoid Salvinorin
A. Pharmacodynamic studies have shown that Salvinorin A
is a potent and selective kappa opioid receptor agonist (Roth
et al., 2002; Chavkin et al., 2004), may exert CB1-like effects,
without being able to activate such receptors (Braida et al.,
2007; Capasso et al., 2008; Fichna et al., 2012; Guida et al.,
2012). In addition Salvinorin A has demonstrated to exert
anti-inflammatory actions (Aviello et al., 2011; Rossi et al.,
2016). Recently, we have demonstrated that its anti-inflammatory
properties, at least in part, were related to ability to inhibit
leukotriene (LT) biosynthesis (Rossi et al., 2016).
Leukotrienes are crucial mediators of allergic diseases, such
as bronchial asthma, allergic rhinitis, and urticaria (Chen
et al., 1994; Schauberger et al., 2016). They are synthesized
from arachidonic acid predominantly by eosinophils, mast cells
and macrophages in response to a variety of stimuli. Five-
lipoxygenase, enzyme responsible of LT biosynthesis, converts
the fatty acid into LTA4, the common precursor for LTB4
and LTC4. Subsequently, LTC4 is converted to LTD4 and
LTE4 (cysteinyl-LTs; cys-LTs). They induce bronchoconstriction,
inflammatory cell recruitment and plasma extravasation, and
drive tissue edema, all these are classical signs of allergic
pulmonary inflammation (Thivierge et al., 2001; Singh et al.,
2013; Schauberger et al., 2016). Furthermore, following allergen
exposure mast cells generate large amounts of cys-LTs, which
in turn induce an autocrine-type amplification of Th2 response
(Vargaftig and Singer, 2003; Kim et al., 2006). In fact activated
mast cells produce several cytokines among which are IL-4 and
-13, which are crucial for the development of asthma features.
In particular there is evidence that IL-4 is crucial for Th2-cell
differentiation from naive T cells. In addition IL-4 causes isotype
class-switching of B cells toward IgE synthesis and it is involved in
mast-cell recruitment and airway hyperresponsivity (Herz et al.,
1998; Ryzhov et al., 2004; Chung, 2015; Ul-Haq et al., 2016).
However, on the other hand, there is evidence that IL-4 may also
reduce the activation of memory CD8 T cells and their following
differentiation in NK cells, affecting in this way the immune
response to pathogens. This could also explain the correlation,
based also on clinical evidence, between a strong Th2 immune
response (characterized by high IL-4 levels) and chronic parasitic
infections (Actor et al., 1993; Ventre et al., 2012), indeed high
levels of IL-4 may deviate the host respone toward a Th2 type. On
the other hand, low levels of IL-4 may increase the susceptibility
to autoimmune diseases (Hill and Sarvetnick, 2002; Ventre et al.,
2012).
Because LTs play a fundamental role in the pathogenesis of
asthma and other allergic diseases (Chen et al., 1994; Schauberger
et al., 2016), in the present study, we have investigated the effect
of Salvinorin A on airways following OVA sensitization. Possibly
relevant to our study, it is intriguing the observation that Internet
sites report recipes for home-made preparations of S. divinorum
advocated to cure bronchial asthma.
Salvinorin A reduced bronchial hyperreactivity by inhibition
of pulmonary mast cell degranulation and in turn, of IL-13 and
LTC4 production.
MATERIALS AND METHODS
Materials
Salvinorin A was isolated from leaves of S. divinorum, extracted
and purified (purity: 99% by HPLC) as described in detail
elsewhere (Capasso et al., 2006). All other reagents and fine
chemicals were obtained from Sigma-Aldrich (Milan, Italy).
Animals
Female BALB/c mice (18± 2 g body weight, Charles River, Calco,
Italy) were housed in a controlled environment (21 ± 2◦C) and
provided with standard rodent chow and water. All animals were
allowed to acclimate for 4 days prior to experiments and were
subjected to 12 h light – 12 h dark schedule. Experiments were
conducted during the light phase. The experimental procedures,
according to Italian (DL 26/2014) and European (n. 63/2010/UE)
regulations on the protection of animals used for experimental
and other scientific purposes, were approved by the Italian
Ministry.
Sensitization and Drug Treatment
Animals were injected with 0.4 ml s.c. of a suspension containing
100 µg of OVA absorbed to 3.3 mg of aluminium hydroxide gel
on days 1 and 8 (OVA-sensitized mice) (Figure 1A) (Das et al.,
1997; Roviezzo et al., 2007, 2015; Sullo et al., 2013). Salvinorin
A (10 mg/kg; Rossi et al., 2016) or vehicle (dimethyl sulfoxide
4%, 0.5 ml) were administered i.p. 30 min before each OVA
administration.
Air Pouch Model
Mice, sensitized as described above, received on days 9 and 12
on the shaved dorsal surface, 2.5 ml s.c. of air to initiate the
development of the air-pouches as described previously (Das
et al., 1997) (Figure 1A). On day 15 (6 days after the first air
injection) animals were challenged by injection into the air-pouch
with 0.4 ml of sterile saline alone or containing 10 µg OVA. At
different time-points (30 min, 2 or 24 h) after OVA or saline
injection into the air-pouch, mice were sacrificed by exposition
to CO2. Air-pouches were washed with 1 ml phosphate-buffered
saline (pH = 7.4). Lavage fluids were centrifuged at 300 × g for
10 min at 4◦C. Supernatants were then collected and stored at
−80◦C until assayed for LTs (Cayman Chemical; BertinPharma,
Montigny Le Bretonneux, France), IL-4 and IL-13 evaluation by
ELISA kits according to manufacturer’s instructions. Levels were
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FIGURE 1 | Effect of Salvinorin A on LT production and cell recruitment in allergen-induced inflammation in air pouch. (A) Scheme of air pouch model.
Animals were injected with 0.4 ml s.c. of a suspension containing 100 µg of OVA absorbed to 3.3 mg of aluminium hydroxide gel on days 1 and 8. Then they
received at days 9 and 12 on the shaved dorsal surface 2.5 ml s.c. of air. On day 15 animals were challenged by injection into the air-pouch with 0.4 ml of sterile
saline alone (vehicle) or containing 10 µg OVA. Salvinorin A (OVA+SA; 10 mg/kg) or vehicle (dimethyl sulfoxide 4%, 0.5 ml; OVA) were administered i.p. 30 min
before each OVA administration. (B) Time-course of LTC4 and LTB4 levels and of cell recruitment in the lavage fluid of air pouch following OVA challenge. (C) LTC4,
and (D) LTB4 levels were quantified in lavage fluid of air pouch 30 min after OVA challenge, while (E) cell recruitment was quantified 24 h after OVA challenge. Data
are expressed as means ± SEM from n = 6 animals for each group. ◦p < 0.05; ◦◦p < 0.01; ◦◦◦p < 0.001 vs. time 0 h; ∗∗p < 0.01; ∗p < 0.05.
expressed as pg/ml. Cell pellets were resuspended in phosphate-
buffered saline and total cell counts were performed following
Trypan blue staining.
Bronchial Reactivity
Ovalbumin-sensitized mice were sacrificed on day 15 and
22 by cervical dislocation, exsanguinated, and lungs were
removed. Main bronchi (22 days after sensitization) were rapidly
dissected and cleaned from fat and connective tissue. Rings
of 1–2 mm length were cut and mounted in 2.5 ml isolated
organ baths containing Krebs solution, at 37◦C, oxygenated
(95% O2 and 5% CO2), and connected to an isometric force
transducer (type 7006, Ugo Basile, Comerio, Italy) associated to
a Powerlab 800 (AD Instruments). Rings were initially stretched
until a resting tension of 0.5 g was reached and allowed
to equilibrate for at least 30 min during which tension was
adjusted, when necessary, to a 0.5 g and bathing solution was
periodically changed. In each experiment bronchial rings were
previously challenged with acetylcholine (10−6 mol/L) until a
reproducible response was obtained. Subsequently, after tissue
washing, a cumulative concentration response curve to carbachol
(10−9 – 3× 10−6 M) was performed. Results were expressed as
dine per mg tissue.
IgE, Cytokine, and LT Measurements
In another set of experiments OVA-sensitized mice were
sacrificed at 15 days to take pulmonary tissues and blood for
biochemical studies and IgE evaluation, respectively. Plasma IgE
levels were measured by means of ELISA using matched antibody
pairs (BD Pharmingen, Franklin Lakes, NJ, USA). Each lung was
divided into two parts. One part was frozen in liquid nitrogen
for 2 h before storage at −80◦C and subsequently homogenate
for cytokine and LT measurements by ELISA, and the other was
fixed in 10% neutralized buffered formalin for histopathological
evaluation. Levels of LTC4 and cytokines were expressed as pg/mg
of tissue.
Lung Histology
Lung sections were cut (7 µm thick) and stained with H&E for
morphological analysis. Mast cell degranulation was evaluated
following the method described by Iuvone et al. (1999). In
brief, it was calculated the percentage of light blue stained cells
following toluidine staining, i.e., degranulated mast cells, on the
total number of mast cells, per mm2. Non-degranulated mast
cells appeared deep blue stained. The sections were analyzed
by blinded operators using a standard light microscope (20×
magnification, for H&E staining, and 40× magnification, for
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FIGURE 2 | Effect of Salvinorin A on IL-4 and IL-13 in allergen-induced inflammation in air pouch. Salvinorin A (OVA+SA; 10 mg/kg) or vehicle (dimethyl
sulfoxide 4%, 0.5 ml; OVA) were administered i.p. 30 min before each OVA administration. (A) Time-course of IL-4 and IL-13 in the lavage fluid of air pouch after OVA
challenge. (B) IL-4 and (C) IL-13 were quantified in lavage fluid of air pouch 2 h after OVA challenge by ELISA. Data are expressed as means ± SEM from n = 6
animals for each group. ◦p < 0.05 vs. time 0 h; ∗p < 0.05.
toluidine blue staining) and photographed under low power.
Images were taken by a Leica DFC320 video-camera (Leica,
Milan, Italy) connected to a Leica DM RB microscope using the
Leica Application Suite software V.4.1.0.
Myeloperoxidase Activity
Myeloperoxidase activity in lung tissues harvested 15 days
after OVA sensitization was determined as previously
described (Rossi et al., 2016). Each piece of tissue was
weighed and then homogenized in a solution containing
0.5% hexadecyltrimethylammonium bromide dissolved in
10 mM phosphate-buffered saline (pH 7) and centrifuged
(30 min at 20,000 × g at 4◦C). An aliquot of the supernatant was
then allowed to react with a solution of tetramethylbenzidine
(1.6 mM) and 0.1 mM H2O2. The rate of change in absorbance
was measured spectrophotometrically at 650 nm. MPO activity
was defined as the quantity of enzyme degrading 1 µmol of
peroxide per minute at 37◦C and was expressed in units per gram
weight of wet tissue.
Statistical Analysis
Data are expressed as mean ± standard error of the mean
(S.E.M.) of n observations, were n represents the number of
animals (at least of six per group for each data set). Statistical
analysis has been performed by using t-test or two-way analysis
of variance (ANOVA) for multiple comparisons followed by
Bonferroni’s post-test [GraphPad Prism 5.0 software (San Diego,
CA, USA)]. Post hoc tests were performed when ANOVAs
indicated that a significant difference existed between groups. All
statistical tests performed showed no significant variance in data
set homogeneity. Data were considered statistically significant
when a value of at least p< 0.05 was achieved.
RESULTS
Salvinorin A Inhibits Allergen-Induced LT
Production in Air Pouch Model
Previously, we demonstrated that Salvinorin A reduced LT
synthesis in experimental models of acute inflammation (Rossi
et al., 2016). Therefore, we investigated the possibility that
this natural diterpene might affect LT production also during
allergic inflammation. For this purpose, we used the air
pouch model in OVA-sensitized and challenged mice (Das
et al., 1997) (Figure 1A). We chose this model since air
pouch provides a convenient cavity from which mediators
and cells can be easily harvested. OVA administration in
the dorsal air pouch of sensitized-mice caused a significant
increase in LTC4 and LTB4 production, which peaked at
30 min and returned to basal levels after 24 h (Figure 1B).
Mouse pre-treatment with Salvinorin A (10 mg/kg, i.p.,
30 min prior each OVA injection) nearly reduced LTC4
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FIGURE 3 | Effect of Salvinorin A on allergen-induced bronchial hyperreactivity. (A) Scheme of sensitization and drug treatment. Mice were injected with
0.4 ml s.c. of a suspension containing 100 µg of OVA absorbed to 3.3 mg of aluminium hydroxide gel on days 1 and 8. After 15 and 22 days after OVA sensitization
mice were sacrificed. Salvinorin A (OVA+SA; 10 mg/kg) or vehicle (dimethyl sulfoxide 4%, 0.5 ml; OVA) were administered i.p. 30 min before each OVA
administration. (B) Bronchial reactivity to carbachol were evaluated 22 days after OVA injection. Insert to figure shows IgE levels in the plasma. Data are expressed as
means ± SEM from n = 6 animals for each group. ∗p < 0.05; ∗∗∗p < 0.001.
and LTB4 production in the lavage fluids of air pouch
(Figures 1C,D).
Salvinorin A Blunts Allergen-Induced
Increase in Cell Recruitment in Air Pouch
Model
In order to assess if the inhibition of LT production was
associated to a reduced inflammatory response, we evaluated
also cell recruitment. Injection of OVA in the air pouch
provoked an intense allergen-dependent cell accumulation that
was significative 2 h after challenge, showing a peak at 24 h
(Figure 1B). Salvinorin A (10 mg/kg, i.p.; 30 min prior each OVA
injection) significantly inhibited OVA-induced cell infiltration in
the air pouch (Figure 1E).
Salvinorin A Abolishes Allergen-Induced
Cytokine Production in Air Pouch Model
Since allergen-induced cell recruitment is sustained by Th2
cytokines, we evaluated if Salvinorin A affected the production
of these mediators. Two hours following OVA challenge, we
observed a significant increase of IL-4 and IL-13 levels into the
pouch of sensitized mice (Figure 2A). Salvinorin A (10 mg/kg,
i.p.; 30 min prior each OVA injection) administration abolished
OVA-induced increase of both Th2 cytokines (Figures 2B,C).
Salvinorin A Counteracts Bronchial
Hyperreactivity in Sensitized Mice
Since Salvinorin A confirmed its ability to affect LT and IL-13
production in an allergic environment, we went on evaluating
its effect on bronchial reactivity of OVA-sensitized mice. To
this aim, we exposed mice to OVA and part of these were pre-
treated with Salvinorin A (10 mg/kg, i.p.; 30 min prior each OVA
injection) (Figure 3A). Bronchial reactivity to carbachol was
assessed. We found that bronchi, excised from OVA-sensitized
mice, showed a significant increased reactivity to carbachol
(Figure 3B) compared to vehicle group. Salvinorin A pre-
treatment reported bronchial reactivity to values measured in
vehicle treated mice (Figure 3B). Conversely, Salvinorin A did
not inhibit OVA-induced IgE up-regulation in the plasma, it
rather further increased their levels (insert to Figure 3).
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FIGURE 4 | Effect of Salvinorin A on allergen-induced pulmonary inflammation. Salvinorin A (OVA+SA; 10 mg/kg) or vehicle (dimethyl sulfoxide 4%, 0.5 ml;
OVA) were administered i.p. 30 min before each OVA administration. H&E staining of lung tissue harvested 15 days after OVA sensitization. H&E staining showing
significant perivascular and peribronchial infiltrates of inflammatory cells in OVA-sensitized mice (B). Vehicle group showed normal appearance of lung parenchyma
(A). Salvinorin A did not inhibit infiltration of inflammatory cells in the lung tissue (C). Insert to figure shows the MPO activity in the lung tissues. ∗∗∗p < 0.001.
Salvinorin A Does Not Affect Pulmonary
Inflammation in Sensitized Mice
Because bronchial hyperreactivity is one of the hallmarks of
asthma and it is closely related to bronchial inflammation, we
extend our study to the evaluation of pulmonary inflammation in
sensitized mice. For this reason, sensitized mice were sacrificed
at 15 days and pulmonary sections used for histology and
biochemical analysis (Figure 4). The data obtained demonstrate
that Salvinorin A (10 mg/kg, i.p.; 30 min prior each OVA
injection) did not affect pulmonary inflammation, as highlighted
by H&E staining (Figure 4). Extensive cell infiltration was still
evident in lung sections of mice pre-treated with Salvinorin
A (Figure 4C), in accordance with high MPO activity
(insert to Figure 4). Furthermore, also peribronchial edema,
present in OVA-sensitized mice (Figure 4B), persisted following
Salvinorin A pre-treatment. In perfect tune with this data,
pulmonary cytokine evaluation evidenced that Salvinorin A
slightly, although not significantly, affected IL-4 up-regulation
(Figure 5A). Conversely, Salvinorin A significantly reduced IL-
13 lung levels accordingly to the inhibitory action on bronchial
hyperreactivity (Figure 5B).
Salvinorin A Inhibits Pulmonary Mast Cell
Degranulation and LTC4 Levels in
Sensitized Mice
Systemic exposure to allergens results in both the production
of IgE against multiple antigen epitopes of several different
antigens and the development of long-term changes in the
involved tissues, including changes in mast cell number,
tissue distribution (with mast cells in the epithelium and
the smooth muscle layer) and phenotype. Binding of IgE to
FcεRI on mast cells, which are normally located in airway
tissues, upregulates FcεRI surface expression and sensitizes
these cells to respond when later exposed to specific antigens,
but also enhance cytokine production and survival (Bradding
et al., 2006). Since direct correlation between mast cell
infiltration and bronchial hyperreactivity exists, we focused
on Salvinorin A effect on mast cell function. As highlighted
by toluidine staining, OVA sensitization significantly increased
mast cell recruitment (Figures 6B,B1,D) into the lung, as
well as their degranulation (Figures 6B,B1,E) when compared
with control (Figures 6A,A1). Salvinorin A (10 mg/kg, i.p.;
30 min prior each OVA injection) did not inhibit mast cell
recruitment, but it further increased it (Figures 6C,C1,D).
Conversely, Salvinorin A inhibited mast cell degranulation
(Figures 6C,C1,E). Since LTC4 is recognized as the main
mediator released by mast cells in allergic asthma, we measured
its levels in the lung; as expected, sensitized mice showed
an increased pulmonary levels of LTC4, effect that was
abrogated when mice were pre-treated with Salvinorin A
(Figure 6F).
DISCUSSION
Recent studies in animal models have revealed that Salvinorin
A exerts a number of pharmacological actions of potential
therapeutic interest which are not solely limited to the central
nervous system (Butelman and Kreek, 2015). These include
attenuation of inflammation (Aviello et al., 2011; Rossi et al.,
2016), inhibition of intestinal motility (Capasso et al., 2008), and
Frontiers in Pharmacology | www.frontiersin.org 6 January 2017 | Volume 7 | Article 525
fphar-07-00525 January 12, 2017 Time: 15:50 # 7
Rossi et al. Salvinorin A Reduces Bronchial Hyperreactivity
FIGURE 5 | Effect of Salvinorin A on IL-4 and IL-13 pulmonary levels in
sensitized-mice. Salvinorin A (OVA+SA; 10 mg/kg) or vehicle (dimethyl
sulfoxide 4%, 0.5 ml; OVA) were administered i.p. 30 min before each OVA
administration. (A) IL-4 and (B) IL-13 were quantified in lung tissue harvested
15 days after OVA sensitization by ELISA. Data are expressed as
means ± SEM from n = 6 animals for each group. ∗p < 0.05.
antipruritic effects (Salaga et al., 2015). The present study has
further expanded the range of the pharmacological actions of this
diterpenoid by evaluating its role in an allergic environment.
Our previous work has provided a deeper insight into the
anti-inflammatory molecular mechanisms of Salvinorin A, by
evidencing its ability to inhibit LT production and LT-related
inflammatory parameters (Rossi et al., 2016). Starting from
such evidence, and considering that LTs are key mediators of
allergic inflammation and critical regulators in the development
of asthma (Singh et al., 2013), we have investigated the effects of
Salvinorin A on allergic inflammation and on airways following
OVA-sensitization in the mouse.
First, we evaluated if the inhibitory effect of Salvinorin A on
LT production persisted also during an inflammatory response
induced by allergic challenge. Specifically, we have used a model
of allergen-induced inflammation into mouse dorsal air pouch
(Das et al., 1997). The air pouch provides a convenient cavity
from which cells and inflammatory mediators can be easily
harvested. It is important to mention that the cell population
found in 6-day-old air pouches of sensitized mice consists
essentially of mononuclear cells (Das et al., 1997). According
to previously published data, injection of OVA into the pouch
of sensitized-mice provoked a slight air pouch cellular influx
starting from 2 h with a peak at 24 h after OVA challenge.
Interestingly, the accumulation of cells appeared as a delayed
event as compared to the rapid LT production (30 min after OVA
challenge), suggesting that LT production by resident cells is a key
event for the following cell recruitment. Indeed, pre-treatment
of sensitized mice with Salvinorin A reduced both LT increase
at the early time (30 min) and the following cell infiltration into
air pouch (24 h).
It has been widely demonstrated in various animal models
that allergic inflammation is primarily dependent on Th2
response, where LT play an important role. In fact the Th2
type inflammatory reaction, characterized by IL-4 and IL-13
production (Lloyd and Hessel, 2010), is suppressed in antigen-
exposed mice deficient of LTC4 synthase (Kim et al., 2006).
Besides it has been reported that LT modifier affect IL-4 and IL-13
production, but not other cytokines in an experimental model of
allergic airway inflammation (Kawano et al., 2014). Accordingly,
in our experimental conditions Salvinorin A significantly reduced
IL-13 and IL-4 levels in the air pouch 2h following OVA
administration.
Collectively, these results demonstrate that Salvinorin A
displays a significant control also of the allergic inflammation and
its beneficial effect is correlated to LT inhibition.
In order to further corroborate our hypothesis and to assess
its potential application, we looked at the effects of Salvinorin A
on airways following OVA sensitization. In particular, we used as
experimental approach a systemic exposure of mice to OVA that
induces an significant increase in plasmatic IgE level. This effect
is coupled to a significant increase in bronchial hyperreactivity
and pulmonary inflammation associated to pulmonary mast cell
recruitment (Roviezzo et al., 2015). Measurements of bronchial
reactivity in vitro evidenced a significant increase in carbachol-
induced contractions, that was reversed by Salvinorin A. This
effect was associated to a reduction of IL-13 levels in the lung
of Salvinorin A pre-treated mice. Our finding is in agreement
with evidence that IL-13 is a cytokine specifically involved in
bronchial hyperreactivity, with a mechanism independent of cell
accumulation or airway mucus production (Venkayya et al.,
2002).
Indeed, the diterpenoid had no effects on inflammatory
response in the lung. Cell infiltration was still evident in
pulmonary sections of lungs harvested from mice pre-treated
with Salvinorin A, such as peribronchial edema. In perfect tune
with this data and accordingly to the high level of IgE found
in sensitized mice pre-treated with Salvinorin A, we observed a
slightly, but not significant inhibition of IL-4 increase in the lung.
Thus, Salvinorin A seems do not affect sensitization mechanisms,
but interferes with effector mechanisms responsible of regulation
of bronchial tone.
Surprisingly, the lack of effect of Salvinorin A on the
development of allergic pulmonary inflammation is not in
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FIGURE 6 | Effect of Salvinorin A on pulmonary mast cell recruitment and degranulation. Salvinorin A (OVA+SA; 10 mg/kg) or vehicle (dimethyl sulfoxide
4%, 0.5 ml; OVA) were administered i.p. 30 min before each OVA administration. (B) In lung of OVA sensitized mice (15 days) there was an increased mast cell
recruitment and degranulation evaluated by Toluidine blue staining (light blue). Lung tissue harvested from Salvinorin A-treated mice (C) showed a further increase in
mast cell recruitment but mostly mast cells were not degranulated (deep blue). (A) Control lung tissue. A1–C1 are field magnification of A, B and C, respectively. (D)
Quantification of cell recruitment and (E) percentage of mast cell degranulation evaluated as ratio between degranulated and total mast cells. (F) LTC4 levels were
quantified in lung tissue by ELISA. Data are expressed as means ± SEM from n = 6 animals for each group. ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001.
line with its effects on air pouch model, in which both cell
recruitment and increased cytokine levels, triggered by allergen
challenge, were inhibited by diterpenoid. This discrepancy
might be due mainly to the differences between the air pouch
cavity and airways in terms of resident and recruited cells. In
addition, it is plausible that Salvinorin A regulates cytokine
production and cell recruitment during the acute phase, but its
relative role may be altered during chronic phase of allergic
inflammation such as in the lung harvested from sensitized
mice (15 days after), when other cell populations come into
play. Accordingly, we also published data demonstrating that
Salvinorin A inhibited neutrophil infiltration as well as MPO
activity in the lung harvested from mice after pleurisy induction
(Rossi et al., 2016). Also in this case the protective effects of
Salvinorin A occurs at early time (4 h) following inflammatory
stimulus.
In order to further gain insight into the cellular mechanisms
underlying the therapeutic effects of Salvinorin A on airway
hyperreactivity, we went on evaluating the role of mast cells.
Although the role of mast cells in experimental asthma models is
still controversial, recently several researchers have demonstrated
the role of innate immune cells in asthma development and in
this context, mast cells seem to play an important role, especially
in the process of sensitization to allergen (Deckers et al., 2013).
Indeed, mast cell infiltration in the smooth muscle is correlated
with responsiveness to cholinergic stimuli as, we have already
demonstrated in our experimental setting (Roviezzo et al., 2015).
In particular, mast cells, armed with specific IgE and residing in
the mucosa, serve as airway sentinels, sensing and responding
to inhaled antigens. In patients with asthma, the IgE-mediated
activation of these cells following allergen exposure induces
release of vasoactive and smooth muscle-constricting mediators,
that trigger acute airflow obstruction, as well as the production
of bioactive lipids, cytokines, and chemokines (Bradding and
Arthur, 2016). However, systemic exposure to allergens results
in both the production of IgE against multiple antigen epitopes
of several different antigens and the development of long-term
changes in the involved tissues, including changes in mast cell
number, tissue distribution (with mast cells in the epithelium
and the smooth muscle layer) and phenotype. Binding of IgE
to FcεRI on mast cells, which are normally located in airway
tissues, upregulates FcεRI surface expression and sensitizes these
cells to respond when later exposed to specific antigens, but,
in mast cells, some IgE molecules can also enhance cytokine
production and cell recruitment (Bradding et al., 2006). All
these events explain the development of bronchial hyperactivity
following sensitization also in absence of an airway challenge.
Our results show that Salvinorin A significantly inhibited mast
cell degranulation in the lung of sensitized mice. This regulatory
effect on mast cells was in according to the recent published
experimental data demonstrating that Salvinorin A analogs
attenuate compound 48/80-induced itch responses in mice
through a KOR-mediated mechanism (Salaga et al., 2015). The
inhibitory action on mast cells, in our experimental conditions,
was confirmed by the significant reduction of lung LTC4 levels.
Conversely Salvinorin A induced a significant increase of mast
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cell number in lungs when compared to OVA-sensitized mice
as well as plasmatic IgE levels. This increase could reflect a
reduction of IgE bound to FcεRI on mast cell surface, consistent
with inhibition of mast cell degranulation. On the other hand
the increase in pulmonary mast cell infiltration could represent
a rebound effect due to the inhibition of mast cell activity,
e.g., degranulation. However, further studies will be necessary to
clarify the molecular mechanisms underlying modulatory action
on mast cells and the beneficial actions of Salvinorin A in
asthma management. In particular it will be interesting to assess
Salvinorin A effects also after repetitive airway challenge in OVA-
sensitized mice or by using other allergenic stimuli such as house
dust mite.
In summary, Salvinorin A does not interfere with sensitization
mechanisms but significantly inhibits airway hyperreactivity
and this effect is sustained by inhibition of mast cell
degranulation/LT production. These characteristics, in addition
to good inhaled pharmacokinetic profile (Johnson et al., 2016),
make Salvinorin A a suitable and promising candidate for drug
development in LT-related allergic inflammatory diseases such as
asthma.
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